# PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas

> **NCT05473923** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent High Grade Glioma

## Interventions

- **DRUG:** Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.

## Key facts

- **NCT ID:** NCT05473923
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-12
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05473923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05473923, "PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05473923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*